This report will outline the research and justification for establishing a European presence in Munich, Germany. I will outline the justification by outlining three primary considerations: proximity, social concerns and cost. This is not a complete strategic plan, only a summary report of the deciding factors and brief justifications.
In the last few years the Munich Biotech Cluster has experienced an exceptional rate of development. Since its inception more than ten years ago, Munich's biotech cluster has emerged as one of the most important in Europe. European ranking tables put Munich in fourth place, In Germany, Munich leads the biotech field. When comparing this to London’s already saturated Biotech Cluster and some of the other undesirable factors of Paris and Budapest (to be discussed later), Munich was by far the obvious choice.
Of particular importance in the ongoing development of commercial biotechnology is the proximity of excellent scientific research institutes, an excellent infrastructure, a sufficient supply of capital, role-models in the form of firms that have already attained success, as well as highly qualified employees. The greater Munich area offers all these needs in an excellent manner (the universities LMU and TUM have gained "excellence-status" in 2006).
Another key factor in choosing Munich as the desired location is its close proximity to the EMEA (European Medicines Agency) and the Biotech Cluster Development GmbH. The EMEA is a decentralized body of the European Union with headquarters in Brussels, Belgium. Its main responsibility is the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use. The Biotech Cluster Development GmbH, located in Munich, will assist in boosting the reputation of the biotech region and foster the attractiveness of BIOTECHA. The final proximity consideration was to the East Coast of the United States. While Munich is not...